[A19-63] Galcanezumab (migraine) - Addendum to commission A19-28
Last updated 19.09.2019
Commission awarded on 05.08.2019 by the Federal Joint Committee (G-BA).
Head and nerves
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-28||Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2019-09-19 A G-BA decision was published.